Lilly plans to invest $3 billion over the next 10 years to boost its manufacturing operations in China, according to a March 11 press release from Lilly’s Chinese operations. Lilly plans to set up local production and supply for oral solid drugs and build out capacity for orforglipron, its experimental GLP-1 pill. Additionally, under a collaboration with Beijing-based CDMO Pharmaron, Lilly will invest $200 million to support its technology and capabilities at the CDMO to expand scale as neede...